

Annual General Meeting

16 July 2008

developing **the difference**

BTG

Forward Looking Statements

This presentation contains certain projections and other "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1985) with respect to the financial condition, results of operations and businesses of BTG plc. These statements are based on current expectations and involve risk and uncertainty because they relate to events and depend upon circumstances that will occur in the future. There are a number of factors which could cause actual results or developments to differ materially from those expressed or implied by these forward looking statements. Although BTG believes that the assumptions underlying these forward looking statements are reasonable, any of the assumptions could prove inaccurate or incorrect and therefore there can be no assurance that any results contemplated in the forward looking statements will be achieved. Nothing in this presentation should be construed as a profit forecast. Investors are cautioned not to place undue reliance on any forward-looking statements contained herein.

BTG

Building A Leading Life Sciences Company

- Focused on building a sustainably profitable business underpinned by a strong development pipeline
  - Neuroscience
  - Selected other indications
- Built on a platform of royalty revenues
- Out-licensed pipeline brings further revenue potential
- Advancing development pipeline funded from internal resources
  - 6 clinical stage programmes

BTG

Results for the Year Ended 31 March 2008

		2007/8 £m		2006/7 £m
Revenue		**75.0**		45.7
Revenue sharing	*43%*	**(32.1)**	*41%*	(18.9)
Revenue net of revenue sharing: recurring	24.9		24.2	
Revenue net of revenue sharing: one-offs	18.0	**42.9**	2.6	26.8
Profit on asset sales less provisions		**0.4**		1.7
Operating & administrative expenses	↓ *11%*	**(16.0)**		(17.9)
R&D expenditure	↑ *10%*	**(10.7)**		(9.7)
Wrexham impairment charges		**(8.1)**		-
Operating profit		**8.5**		0.9
Financial income		**2.2**		1.7
Profit before tax		**10.7**		2.6
Withholding & other taxes		**(1.9)**		(0.2)
Profit after tax		**8.8**		2.4

BTG

Major Products: Gross Licence Revenues

	2007/8 gross revenues £m	2006/7 gross revenues £m	Underlying growth ($ denominated)	Patent coverage
BeneFIX®	**16.9**	15.8	14%	2011
Two-part hip cup	**8.5**	8.6	5%	2019
Campath®	**5.0**	4.5	18%	2017
MRC humanisation IP	**4.1**	3.4		2015
Three-part knee	**2.3**	2.2		2011
Other licences	**5.6**	6.8		2011 average
Total Royalties	**42.4**	41.3		
One-off transactions	**32.6**	4.4		
Total revenues	**75.0**	45.7		

BTG

Increasing Profit Before R&D Costs - increasing operating surplus



* Excludes Wrexham write-off of £8.1m

BTG

Performance Since 1 April 2008 and Outlook

- Overall operational progress and financial performance in line with expectations
  - Milestone received from Cougar Biotechnology on start of phase III trial of CB7630 in advanced prostate cancer
- Additional one-off receipts expected
  - Start of phase III trial of TRX4 in type 1 diabetes
  - Completion of acquisition of Protez by Novartis
- Reduced revenue-sharing obligations on BeneFIX®
- Targeting R&D investment in the range £10-£15m, admin costs similar to last year
- Strong cash position to be maintained

BTG

BTG Development Programmes



BTG

Varisolve® Polidocanol Endovenous Microfoam

- More than 600 patients treated
  - Efficacy of over 85% observed in a Phase III trial
- US Phase II safety study complete
  - 28-day MRIs completed by end June as planned
  - No MRI lesions caused by treatment with Varisolve®
  - Results will be submitted for presentation at American College of Phlebology in Nov. 2008
- Development of new device presentation
- Contact initiated with potential partners

BTG

Varisolve® - Development Pathway

- Pilot Phase III studies to validate endpoints in Phase III trials to start in Q3 08
- Programme to be ready for initiation of Phase III in early 2009
  - Two Phase III trials to focus on symptoms and appearance of varicose veins
  - One trial to assess efficacy in treating venous leg ulcers
- Development plan leads to NDA submission in 2011 and potential US launch in 2012
- Patents and patent applications through 2024

BTG

Varisolve® - Significant Commercial Potential

- Varisolve® is potentially the 1st FDA-approved non-surgical drug treatment able to treat all varicose veins
- Provides significant benefits to patients (brief, painless and short recovery time) and physicians (less dedicated physician time, reduced personnel requirements, comprehensive treatment)
- Market research indicates peak sales potential of over $500m pa in the US reimbursed sector alone
  - Prevalence ~25%, but fewer than 1% receive treatment
  - GSV procedures, veins not currently treatable by existing methods, visible varicosities, adjunct procedures to other GSV treatments and leg ulcers
  - Potential reimbursement under Medicare Part B
- Additional opportunities
  - US self-pay market
  - RoW markets

BTG

BGC20-0166 – Obstructive Sleep Apnoea

- Potentially the 1st pharmacological agent for OSA – an under-diagnosed condition and significant unmet need
  - Only 30% of suffers / 3.7m people diagnosed
  - Only effective treatment is CPAP mask, which is recommended for 75% of diagnosed patients (but poor compliance)
  - CPAP market worth over $1bn pa
- BGC20-0166 developed as alternative to CPAP / to increase compliance
- Projected diagnosed patient population to increase to 6.6m people in 2015
  - Driven by better awareness, increased diagnosis
  - 4.6m in the mild-moderate category: target for BGC20-0166

BTG

BGC20-0166 – Promising Clinical Results

- Positive results from proof of concept clinical study
  - 39 patients received a single agent, high- or low-dose combination for 28 days and AHI measured at 14 and 28 days
- High-dose group experienced statistically significant 40% reduction (range 10%-85%) in AHI at 28 days (1° endpoint)
  - 3 complete responders: AHI fell >50% and final AHI < 10
  - AHI reduced in REM and non-REM sleep, no impact on sleep architecture – unlike other drugs studied previously
- Non-clinical studies, a clinical pK study and formulation work are continuing in anticipation of an IND filing

BTG

BGC20-0582 – Head Lice Infestation

- Phase II study completed – 230 subjects randomised to 3 doses of BGC20-0582 as a topical gel formulation
- No significant increase in cure rate at 14 days compared with placebo: 64.7% cure rate for 10% dose vs 52.6% for placebo
  - Very high placebo response
- Statistically significant combined cure / re-infestation efficacy of 76.5% for 10% dose vs 56.1% for placebo
  - Compares favourably to efficacy rate observed for leading OTC product in studies of similar design and subject demographics
- *In vitro* study under way to investigate pediculocidal resistance compared with leading OTC products

BTG

BGC20-1259 – Alzheimer's Disease

- Acts on both cognitive and mood aspects of age-related dementia
  - Renewed research focus on improving treatment of symptoms, quality of life in addition to finding disease-modifying agents
- Well-tolerated in completed Phase I studies
  - Positive effects in cognitive test battery and self-reported mood in repeat dose study
- EU Phase II study in Alzheimer's patients planned for H2 08
  - ~240 patients with mild to moderate AD, randomised to 1 of 3 doses or placebo, 6 months treatment duration
  - Assess safety and efficacy – cognitive performance, quality of life and behavioural/psychiatric symptoms

BTG

BGC20-1531 – Migraine Headache

- Migraine headache affects 10-20% of population (WHO)
- Current treatments are mainly NSAIDs and triptans
  - ~40% of sufferers do not experience sufficient relief or cannot tolerate the GI, CV or other side effects
- BGC20-1531 is a prostaglandin EP4 receptor antagonist that inhibits PGE2-induced vasodilatation of cranial blood vessels
  - Discrete localisation of EP4 receptors may confer improved safety profile compared to current treatments
- Phase I rising dose study commenced in early 2008 to assess safety, tolerability and pharmacokinetic profile
  - Dosing of 3rd and final cohort under way
- Phase II planned to start H1 09

BTG

BGC20-0134 – Multiple Sclerosis

- MS affects around 2.5m people worldwide (WHO)
  - Most patients are diagnosed with relapsing-remitting MS
  - Current marketed treatments are of limited benefit in MS
- Cause unknown, but strong evidence for involvement of autoimmune processes; dysregulation of cytokines observed
- BGC20-0134 is a novel structured lipid designed to restore the balance between pro- and anti-inflammatory cytokines
  - Prototype compound showed clinical benefits in RRMS patients and was very well tolerated
- Dosing has completed in a combined single and repeat rising-dose Phase I study of oral BGC20-0134
- Phase II planned to start H1 09

BTG

Progress in Key Licensed Programmes



BTG

- Campath® - CLL, MS (Genzyme)
  - Approved as 1st-line treatment for CLL
  - Two Phase III trials under way in MS
  - Positive three-year data reported at AAN
    - » 73% reduction in risk for relapse and 71% reduction in risk for sustained accumulation of disability compared with Rebif®
    - » Side effects treatable and manageable
- TRX4 – Type 1 diabetes, inflammatory disorders (Tolerx)
  - Collaboration with GSK to develop for a range of diseases
  - Phase III trial in type 1 diabetes anticipated to commence in 08
    - » Triggers further milestone payment to BTG

BTG

- CB7630 (abiraterone acetate) – prostate cancer (Cougar)
  - Positive Phase I/II study results reported
  - Phase III trial commenced enrolment in April 08
    - Randomised, double-blind, placebo-controlled trial of CB7630 plus prednisone in patients with metastatic castration-resistant prostate cancer who have failed docetaxel-based chemotherapy
    - Targets enrolling ~1160 patients at 150 sites
    - Primary endpoint is overall survival
    - Triggered milestone payment to BTG

BTG

Anticipated Development Milestones

- H2 08
  - Conduct Varisolve® pre-Phase III studies and present results of Phase II safety study at ACP
  - Complete Phase I study of BGC20-0134
  - Complete Phase I study of BGC20-1531
  - Initiate Phase II study of BGC20-1259
  - TRX4 to commence Phase III

- H1 09
  - Varisolve® Phase III ready
  - Commence Phase II studies of BGC 20-0134 and BGC20-1531
  - File IND for BGC20-0166

BTG

Summary

- Strong financial position
  - Recurring revenues
  - One-off receipts
  - Cash
- Pipeline momentum - 6 clinical development programmes
  - Varisolve®, 1259, 0166, 0582, 1531, 0134
- Licensed products moving forward
  - Campath® in Phase III in MS, CB7630 in Phase III in prostate cancer
  - TRX4 to start Phase III in type 1 diabetes
- Focused on driving business towards sustainable profitability

BTG



Annual General Meeting

16 July 2008

developing **the difference**

BTG